Efek Ganja Medis pada Pasien Parkinson: A Literature Review of Clinical Evidence

Rita Komalasari

Abstract


Ganja atau ganja medis adalah obat psikedelik yang terdiri dari komponen tinggi lipofilik tetrahydrocannabinol (THC) dan Cannabidiol (CBD) yang berasal dari tanaman C. sativa dan C. indica. Penyakit Parkinson (PP), di mana interaktivitas jalur sinyal biokimia dan seluler menginduksi sistem kanabinoid endogen, sistem neuromodulatory, mentransmisikan efek fisiologis spesifik ketika dipasangkan dengan reseptor G-protein-coupled (GPCR) melalui reseptor kanabinoid tipe 1 (CB1) dan reseptor kanabinoid tipe 2 (CB2), merintis perubahan dalam sistem saraf dan kekebalan tubuh. Banyak penelitian terbaru menunjukkan bahwa interaksi antara sistem ganja dan dopamin di daerah ganglia basal mengurangi diskinesia (LID) akibat levodopa dan gejala lainnya. Karena terbatasnya pilihan pengobatan farmakologi yang tersedia untuk PP, penelitian mendalam dengan uji klinis sangat penting dalam pencarian molekul dengan studi potensial terapeutik dalam berbagai pekerjaan epidemiologi PP untuk meningkatkan transmisi saraf. Makalah ini mengulas modus tindakan cannabinoid dalam PP.

Keywords


Efek Fisiologis Spesifik; Zat Halusinasi

References


Marras C, Beck JC, Bower JH, Roberts E, Ritz B, Ross GW, Abbott RD, Savica R, Van Den Eeden SK, Willis AW, Tanner CM. Prevalence of Parkinson’s disease across North America. NPJ Parkinson's disease. 2018 Jul 10;4(1):1-7.

Schapira AH, Chaudhuri K, Jenner P. Non-motor features of Parkinson disease. Nature Reviews Neuroscience. 2017 Jul;18(7):435-50.

Gauthier S, Rosa-Neto P, Morais JA, Webster C. World Alzheimer Report 2021: Journey through the diagnosis of dementia. Alzheimer’s Disease International. 2021.

Donley S, McGregor S, Wielinski C, Nance M. Use and perceived effectiveness of complementary therapies in Parkinson's disease. Parkinsonism & related disorders. 2019 Jan 1;58:46-9.

Zheng C, Zhang F. New insights into pathogenesis of l-DOPA-induced dyskinesia. NeuroToxicology. 2021 Sep 1;86:104-13.

Akinyemi E, Randhawa G, Longoria V, Zeine R. Medical marijuana effects in movement disorders, focus on huntington disease; a literature review. Journal of Pharmacy & Pharmaceutical Sciences. 2020 Oct 14;23:389-95.

Stasiulewicz A, Znajdek K, Grudzień M, Pawiński T, Sulkowska JI. A guide to targeting the endocannabinoid system in drug design.

International journal of molecular sciences. 2020 Jan;21(8):2778.

Cristino L, Bisogno T, Di Marzo V. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nature Reviews Neurology. 2020 Jan;16(1):9-29.

Maayah ZH, Takahara S, Ferdaoussi M, Dyck JR. The molecular mechanisms that underpin the biological benefits of full-spectrum cannabis extract in the treatment of neuropathic pain and inflammation. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2020 Jul 1;1866(7):165771.

Reynoso-Moreno I, Tietz S, Vallini E, Engelhardt B, Gertsch J, Chicca A. Selective endocannabinoid reuptake inhibitor WOBE437 reduces disease progression in a mouse model of multiple sclerosis. ACS pharmacology & translational science. 2021 Mar 26;4(2):765-79.

Patricio F, Morales-Andrade AA, Patricio-Martínez A, Limón ID. Cannabidiol as a therapeutic target: evidence of its neuroprotective and neuromodulatory function in Parkinson’s disease. Frontiers in Pharmacology. 2020 Dec 15;11:595635.

Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, Abate M, Faggiana G, Proto MC, Fiore D, Laezza C. Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacology & therapeutics. 2017 Jul 1;175:133-50.

Suryadevara U, M Bruijnzeel D, Nuthi M, A Jagnarine D, Tandon R, W Bruijnzeel A. Pros and cons of medical cannabis use by people with chronic brain disorders. Current neuropharmacology. 2017 Aug 1;15(6):800-14.

Kindred JH, Li K, Ketelhut NB, Proessl F, Fling BW, Honce JM, Shaffer WR, Rudroff T. Cannabis use in people with Parkinson’s disease and Multiple Sclerosis: A web-based investigation. Complementary therapies in medicine. 2017 Aug 1;33:99-104.

Latif Z, Garg N. The impact of marijuana on the cardiovascular system: a review of the most common cardiovascular events associated with marijuana use. Journal of clinical medicine. 2020 Jun 19;9(6):1925.

Tysnes OB, Storstein A. Epidemiology of Parkinson’s disease. Journal of neural transmission. 2017 Aug;124(8):901-5.




DOI: https://doi.org/10.18860/jip.v8i1.17832

Refbacks

  • There are currently no refbacks.


Copyright (c) 2023 Journal of Islamic Pharmacy

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

© 2023 Journal of Islamic Pharmacy